☰

Kipp Weiskopf - Publications

Affiliations: 
Whitehead Institute for Biomedical Research (MIT) 
Area:
Cancer Immunotherapy
Tree Info Similar researchers PubMed Report error

53 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Vaccaro K, Allen J, Whitfield TW, Maoz A, Reeves S, Velarde J, Yang D, Meglan A, Ribeiro J, Blandin J, Phan N, Bell GW, Hata A, Weiskopf K. Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction. The Journal of Clinical Investigation. PMID 38483480 DOI: 10.1172/JCI169315  0.493
2023 Vaccaro K, Allen J, Whitfield TW, Maoz A, Reeves S, Velarde J, Yang D, Phan N, Bell GW, Hata AN, Weiskopf K. Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction. Biorxiv : the Preprint Server For Biology. PMID 36945559 DOI: 10.1101/2023.03.03.531059  0.5
2019 Anderson KL, Snyder KM, Ito D, Lins DC, Mills LJ, Weiskopf K, Ring NG, Ring AM, Shimizu Y, Mescher MF, Weissman IL, Modiano JF. Evolutionarily conserved resistance to phagocytosis observed in melanoma cells is insensitive to upregulation of pro-phagocytic signals and to CD47 blockade. Melanoma Research. PMID 31205227 DOI: 10.1097/Cmr.0000000000000629  0.806
2019 Kohrt HE, Colevas AD, Houot R, Weiskopf K, Goldstein MJ, Lund P, Mueller A, Sagiv-Barfi I, Marabelle A, Lira R, Troutner E, Richards L, Rajapaska A, Hebb J, Chester C, et al. Targeting CD137 enhances the efficacy of cetuximab. The Journal of Clinical Investigation. 129: 2595. PMID 31157621 DOI: 10.1172/JCI129689  0.405
2019 Kohrt HE, Houot R, Weiskopf K, Goldstein MJ, Scheeren F, Czerwinski D, Colevas AD, Weng WK, Clarke MF, Carlson RW, Stockdale FE, Mollick JA, Chen L, Levy R. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. The Journal of Clinical Investigation. 129: 2595. PMID 31157620 DOI: 10.1172/JCI129688  0.42
2019 Anderson KL, Snyder KM, Ito D, Lins DC, Mills LJ, Weiskopf K, Ring NG, Ring AM, Shimizu Y, Mescher MF, Weissman IL, Modiano JF. Abstract A051: Melanoma displays an evolutionarily conserved resistance to upregulation of prophagocytic signals and to CD47 blockade Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-A051  0.83
2018 Barkal AA, Weiskopf K, Kao KS, Gordon SR, Rosental B, Yiu YY, George BM, Markovic M, Ring NG, Tsai JM, McKenna KM, Ho PY, Cheng RZ, Chen JY, Barkal LJ, et al. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nature Immunology. 19: 76-84. PMID 29180808 DOI: 10.1038/S41590-017-0004-Z  0.754
2017 Ring NG, Herndler-Brandstetter D, Weiskopf K, Shan L, Volkmer JP, George BM, Lietzenmayer M, McKenna KM, Naik TJ, McCarty A, Zheng Y, Ring AM, Flavell RA, Weissman IL. Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity. Proceedings of the National Academy of Sciences of the United States of America. PMID 29158380 DOI: 10.1073/Pnas.1710877114  0.862
2017 Hu MS, Walmsley GG, Barnes LA, Weiskopf K, Rennert RC, Duscher D, Januszyk M, Maan ZN, Hong WX, Cheung AT, Leavitt T, Marshall CD, Ransom RC, Malhotra S, Moore AL, et al. Delivery of monocyte lineage cells in a biomimetic scaffold enhances tissue repair. Jci Insight. 2. PMID 28978794 DOI: 10.1172/Jci.Insight.96260  0.427
2017 Weiskopf K. Cancer immunotherapy targeting the CD47/SIRPα axis. European Journal of Cancer (Oxford, England : 1990). 76: 100-109. PMID 28286286 DOI: 10.1016/J.Ejca.2017.02.013  0.642
2017 Anderson KL, Snyder KM, Lins D, Weiskopf K, Shimizu Y, Weissman I, Mescher M, Modiano J. Abstract A65: Mechanisms of melanoma cell resistance to phagocytosis Cancer Immunology Research. 5. DOI: 10.1158/2326-6074.Tumimm16-A65  0.636
2016 Weiskopf K, Anderson KL, Ito D, Schnorr PJ, Tomiyasu H, Ring AM, Bloink K, Efe J, Rue S, Lowery D, Barkal A, Prohaska S, McKenna KM, Cornax I, O'Brien TD, et al. Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20. Cancer Immunology Research. PMID 27856424 DOI: 10.1158/2326-6066.Cir-16-0105  0.837
2016 Weiskopf K, Schnorr PJ, Pang WW, Chao MP, Chhabra A, Seita J, Feng M, Weissman IL. Myeloid Cell Origins, Differentiation, and Clinical Implications. Microbiology Spectrum. 4. PMID 27763252 DOI: 10.1128/Microbiolspec.Mchd-0031-2016  0.803
2016 Chhabra A, Ring AM, Weiskopf K, Schnorr PJ, Gordon S, Le AC, Kwon HS, Ring NG, Volkmer J, Ho PY, Tseng S, Weissman IL, Shizuru JA. Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy. Science Translational Medicine. 8: 351ra105. PMID 27510901 DOI: 10.1126/Scitranslmed.Aae0501  0.781
2016 Ngo M, Han A, Lakatos A, Sahoo D, Hachey SJ, Weiskopf K, Beck AH, Weissman IL, Boiko AD. Antibody Therapy Targeting CD47 and CD271 Effectively Suppresses Melanoma Metastasis in Patient-Derived Xenografts. Cell Reports. PMID 27477289 DOI: 10.1016/J.Celrep.2016.07.004  0.861
2016 Weiskopf K, Jahchan NS, Schnorr PJ, Cristea S, Ring AM, Maute RL, Volkmer AK, Volkmer JP, Liu J, Lim JS, Yang D, Seitz G, Nguyen T, Wu D, Jude K, et al. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. The Journal of Clinical Investigation. PMID 27294525 DOI: 10.1172/Jci81603  0.826
2016 Piccione EC, Juarez S, Tseng S, Liu J, Stafford M, Narayanan C, Wang L, Weiskopf K, Majeti R. SIRPα-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27126995 DOI: 10.1158/1078-0432.Ccr-15-2503  0.758
2016 Torchia J, Weiskopf K, Levy R. Targeting lymphoma with precision using semisynthetic anti-idiotype peptibodies. Proceedings of the National Academy of Sciences of the United States of America. 113: 5376-81. PMID 27114517 DOI: 10.1073/Pnas.1603335113  0.459
2016 Krampitz GW, George BM, Willingham SB, Volkmer JP, Weiskopf K, Jahchan N, Newman AM, Sahoo D, Zemek AJ, Yanovsky RL, Nguyen JK, Schnorr PJ, Mazur PK, Sage J, Longacre TA, et al. Identification of tumorigenic cells and therapeutic targets in pancreatic neuroendocrine tumors. Proceedings of the National Academy of Sciences of the United States of America. PMID 27035983 DOI: 10.1073/Pnas.1600007113  0.82
2015 Piccione EC, Juarez S, Liu J, Tseng S, Ryan C, Narayanan C, Wang L, Weiskopf K, Majeti R. A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells. Mabs. 0. PMID 26083076 DOI: 10.1080/19420862.2015.1062192  0.768
2015 Mitra S, Ring AM, Amarnath S, Spangler JB, Li P, Ju W, Fischer S, Oh J, Spolski R, Weiskopf K, Kohrt H, Foley JE, Rajagopalan S, Long EO, Fowler DH, et al. Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps. Immunity. 42: 826-38. PMID 25992859 DOI: 10.1016/J.Immuni.2015.04.018  0.619
2015 Ho CC, Guo N, Sockolosky JT, Ring AM, Weiskopf K, Özkan E, Mori Y, Weissman IL, Garcia KC. "Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis. The Journal of Biological Chemistry. 290: 12650-63. PMID 25837251 DOI: 10.1074/Jbc.M115.648220  0.816
2015 Weiskopf K, Weissman IL. Macrophages are critical effectors of antibody therapies for cancer. Mabs. 7: 303-10. PMID 25667985 DOI: 10.1080/19420862.2015.1011450  0.637
2015 Weiskopf K, Ring A, Garcia KC, Weissman I. CD47-blocking therapies stimulate macrophage cytokine secretion and are effective in a model of peritoneal carcinomatosis Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P248  0.826
2015 Walmsley GG, Hu MS, Weiskopf K, Maan ZN, Duscher D, Rennert R, Januszyk M, Tevlin R, Atashroo D, Seanarath-Yapa K, Whittam A, Zielins E, Marecic O, Lorenz HP, Weissman IL, et al. Abstract P18 Plastic and Reconstructive Surgery. 135: 135-136. DOI: 10.1097/01.Prs.0000465644.78926.A9  0.331
2015 Krampitz GW, Willingham SB, Volkmer JP, Weiskopf KA, George BM, Sage J, Visser BC, Poultsides GA, Norton JA, Weissman IL. Identification of Tumorigenic Cells and Therapeutic Targets in Pancreatic Neuroendocrine Cancers Journal of the American College of Surgeons. 221: S59-S60. DOI: 10.1016/J.Jamcollsurg.2015.07.130  0.795
2015 Chhabra A, Ring A, Weiskopf K, Schnorr PJ, Gordon S, Le AC, Kwon H, Guo N, Volkmer J, Ho PY, Tseng S, Weissman I, Shizuru J. HSC transplantation in an immunocompetent host without radiation or chemotherapy Experimental Hematology. 43: S57. DOI: 10.1016/J.Exphem.2015.06.101  0.731
2014 Kohrt HE, Colevas AD, Houot R, Weiskopf K, Goldstein MJ, Lund P, Mueller A, Sagiv-Barfi I, Marabelle A, Lira R, Troutner E, Richards L, Rajapaska A, Hebb J, Chester C, et al. Targeting CD137 enhances the efficacy of cetuximab. The Journal of Clinical Investigation. 124: 2668-82. PMID 24837434 DOI: 10.1172/Jci73014  0.614
2014 Weiskopf K, Ring AM, Guo N, Schnorr PJ, Maute RL, Volkmer J, Weissman IL. Direct SIRPa Blockade Augments Macrophage Responses to Therapeutic Anticancer Antibodies Blood. 124: 2729-2729. DOI: 10.1182/Blood.V124.21.2729.2729  0.838
2014 Chhabra A, Ring AM, Weiskopf K, Weissman IL, Shizuru JA. Successful Engraftment of Hematopoietic Stem Cells into Immunocompetent Recipients Using Only Anti-CD117 Antibody and CD47 Blockade As Conditioning Blood. 124: 2410-2410. DOI: 10.1182/Blood.V124.21.2410.2410  0.824
2014 Torchia J, Ng P, Chen H, Weiskopf K, Levy R. Abstract 648: Semi-synthetic peptibodies are a novel personalized therapeutic with activity against lymphomain vitroandin vivo Cancer Research. 74: 648-648. DOI: 10.1158/1538-7445.Am2014-648  0.459
2014 Weiskopf K, Schnorr PJ, Jahchan N, Ring AM, Maute RL, Volkmer AK, Volkmer J, Garcia KC, Sage J, Weissman IL. Abstract 3629: Overcoming macrophage immunosuppression in small cell lung cancer with high-affinity SIRPa variants Cancer Research. 74: 3629-3629. DOI: 10.1158/1538-7445.Am2014-3629  0.867
2014 Hu M, Walmsley G, Weiskopf K, Rennert R, Rajadas J, Gurtner G, Weissman I, Lorenz HP, Longaker M. Abstract P44 Plastic and Reconstructive Surgery. 133: 222-223. DOI: 10.1097/01.Prs.0000445044.24333.86  0.331
2014 Walmsley G, Hu M, Weiskopf K, Rennert R, McArdle A, Chung M, Schnorr P, Rajadas J, Gurtner G, Weissman I, Lorenz H, Longaker M. Macrophage Transplantation Improves Cutaneous Wound Healing in a Humanized Mouse Model Journal of Surgical Research. 186: 648. DOI: 10.1016/J.Jss.2013.11.681  0.771
2014 Walmsley G, Hu M, Weiskopf K, Rennert R, McArdle A, Chung M, Schnorr P, Rajadas J, Gurtner G, Weissman I, Lorenz H, Longaker M. Macrophage Transplantation Improves Cutaneous Wound Healing in a Humanized Mouse Model Journal of Surgical Research. 186: 521. DOI: 10.1016/j.jss.2013.11.366  0.772
2013 Weiskopf K, Ring AM, Schnorr PJ, Volkmer JP, Volkmer AK, Weissman IL, Garcia KC. Improving macrophage responses to therapeutic antibodies by molecular engineering of SIRPα variants. Oncoimmunology. 2: e25773. PMID 24319639 DOI: 10.4161/Onci.25773  0.844
2013 Edris B, Willingham S, Weiskopf K, Volkmer AK, Volkmer JP, Mühlenberg T, Weissman IL, van de Rijn M. Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors. Oncoimmunology. 2: e24452. PMID 23894705 DOI: 10.4161/Onci.24452  0.5
2013 Weiskopf K, Ring AM, Ho CC, Volkmer JP, Levin AM, Volkmer AK, Ozkan E, Fernhoff NB, van de Rijn M, Weissman IL, Garcia KC. Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies. Science (New York, N.Y.). 341: 88-91. PMID 23722425 DOI: 10.1126/Science.1238856  0.836
2013 Tseng D, Volkmer JP, Willingham SB, Contreras-Trujillo H, Fathman JW, Fernhoff NB, Seita J, Inlay MA, Weiskopf K, Miyanishi M, Weissman IL. Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proceedings of the National Academy of Sciences of the United States of America. 110: 11103-8. PMID 23690610 DOI: 10.1073/Pnas.1305569110  0.825
2013 Edris B, Willingham SB, Weiskopf K, Volkmer AK, Volkmer JP, Mühlenberg T, Montgomery KD, Contreras-Trujillo H, Czechowicz A, Fletcher JA, West RB, Weissman IL, van de Rijn M. Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth. Proceedings of the National Academy of Sciences of the United States of America. 110: 3501-6. PMID 23382202 DOI: 10.1073/Pnas.1222893110  0.779
2013 Kohrt HE, Houot R, Weiskopf K, Goldstein M, Lund P, Lira RR, Troutner E, Richards L, Rajapaksa A, Ostashko A, Weng W, Chen L, Czerwinski D, Colevas AD, Sunwoo J, et al. Targeting CD137 to enhance the antitumor efficacy of cetuximab by stimulation of innate and adaptive immunity. Journal of Clinical Oncology. 31: 3015-3015. DOI: 10.1200/Jco.2013.31.15_Suppl.3015  0.646
2012 Edris B, Weiskopf K, Weissman IL, van de Rijn M. Flipping the script on macrophages in leiomyosarcoma. Oncoimmunology. 1: 1202-1204. PMID 23170280 DOI: 10.4161/Onci.20799  0.688
2012 Verdoes M, Edgington LE, Scheeren FA, Leyva M, Blum G, Weiskopf K, Bachmann MH, Ellman JA, Bogyo M. A nonpeptidic cathepsin S activity-based probe for noninvasive optical imaging of tumor-associated macrophages. Chemistry & Biology. 19: 619-28. PMID 22633413 DOI: 10.1016/J.Chembiol.2012.03.012  0.388
2012 Edris B, Weiskopf K, Volkmer AK, Volkmer JP, Willingham SB, Contreras-Trujillo H, Liu J, Majeti R, West RB, Fletcher JA, Beck AH, Weissman IL, van de Rijn M. Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proceedings of the National Academy of Sciences of the United States of America. 109: 6656-61. PMID 22451919 DOI: 10.1073/Pnas.1121629109  0.776
2012 Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD, Lovelace P, Scheeren FA, Chao MP, Weiskopf K, Tang C, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proceedings of the National Academy of Sciences of the United States of America. 109: 6662-7. PMID 22451913 DOI: 10.1073/Pnas.1121623109  0.853
2012 Kohrt HE, Houot R, Weiskopf K, Goldstein MJ, Scheeren F, Czerwinski D, Colevas AD, Weng WK, Clarke MF, Carlson RW, Stockdale FE, Mollick JA, Chen L, Levy R. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. The Journal of Clinical Investigation. 122: 1066-75. PMID 22326955 DOI: 10.1172/Jci61226  0.535
2012 Kohrt HE, Houot R, Weiskopf K, Goldstein M, Lund P, Scheeren F, Czerwinski D, Colevas AD, Weng W, Clarke MF, Carlson RW, Sunwoo J, Tedder T, Chen L, Levy R. Effect of stimulation of natural killer cells with an anti-CD137 mAb on the efficacy of trastuzumab, cetuximab, and rituximab. Journal of Clinical Oncology. 30: 2514-2514. DOI: 10.1200/Jco.2012.30.15_Suppl.2514  0.636
2012 Kohrt H, Houot R, Weiskopf K, Goldstein M, Lund P, Czerwinski D, Sunwoo J, Tedder T, Chen L, Levy R. Abstract LB-138: Stimulation of natural killer cells with an anti-CD137 antibody enhances the efficacy trastuzumab, cetuximab, and rituximab in HER2-expressing breast cancer, EGFR+ head and neck cancer, and CD20+ lymphoma Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-138  0.639
2012 Willingham SB, Volkmer JP, Weiskopf K, Ring AM, Weissman IL. Reply to Soto-Pantoja et al. and Zhao et al.: Targeting CD47 on human solid tumors Proceedings of the National Academy of Sciences of the United States of America. 109: E2844-E2845. DOI: 10.1073/Pnas.1209743109  0.798
2011 Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, Müller A, Pachynski R, Czerwinski D, Coutre S, Chao MP, Chen L, Tedder TF, Levy R. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood. 117: 2423-32. PMID 21193697 DOI: 10.1182/Blood-2010-08-301945  0.624
2010 Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J, Weiskopf K, Willingham SB, Raveh T, Park CY, Majeti R, Weissman IL. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Science Translational Medicine. 2: 63ra94. PMID 21178137 DOI: 10.1126/Scitranslmed.3001375  0.866
2010 Kohrt HE, Houot R, Goldstein M, Weiskopf K, Chen L, Tedder T, Levy R. CD137 stimulation of natural killer cells to enhance the antilymphoma activity of rituximab. Journal of Clinical Oncology. 28: 8068-8068. DOI: 10.1200/Jco.2010.28.15_Suppl.8068  0.558
2010 Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Chao M, Chen L, Tedder T, Levy R. Immunomodulation of NK Cells through 4-1BB (CD137) to Improve the Anti-Lymphoma Activity of Rituximab: Antibody-Based Anti-Lymphoma Synergy Blood. 116: 422-422. DOI: 10.1182/Blood.V116.21.422.422  0.62
Show low-probability matches.